417 related articles for article (PubMed ID: 14582454)
21. Effect of the ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages.
Murakami S; Yamagishi I; Asami Y; Sato M; Tomisawa K
Cell Mol Biol (Noisy-le-grand); 1996 Sep; 42(6):865-72. PubMed ID: 8891354
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone.
Yang L; Yang JB; Chen J; Yu GY; Zhou P; Lei L; Wang ZZ; Cy Chang C; Yang XY; Chang TY; Li BL
Cell Res; 2004 Aug; 14(4):315-23. PubMed ID: 15353128
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
[TBL] [Abstract][Full Text] [Related]
24. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs.
Alegret M; Llaverias G; Silvestre JS
Methods Find Exp Clin Pharmacol; 2004 Sep; 26(7):563-86. PubMed ID: 15538545
[TBL] [Abstract][Full Text] [Related]
25. Stimulation of cholesterol release from rabbit foam cells by the action of a new inhibitor for acyl CoA:cholesterol acyltransferase (ACAT), HL-004.
Ishii I; Yokoyama N; Yanagimachi M; Ashikawa N; Hata M; Murakami S; Asami Y; Morisaki N; Saito Y; Ohmori S; Kitada M
J Pharmacol Exp Ther; 1998 Oct; 287(1):115-21. PubMed ID: 9765329
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
Liang K; Vaziri ND
Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E676-81. PubMed ID: 12217884
[TBL] [Abstract][Full Text] [Related]
27. Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion.
Burnett JR; Wilcox LJ; Huff MW
Clin Chim Acta; 1999 Aug; 286(1-2):231-42. PubMed ID: 10511295
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
de Medina P; Payré BL; Bernad J; Bosser I; Pipy B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1165-73. PubMed ID: 14617686
[TBL] [Abstract][Full Text] [Related]
29. The lipid-laden foam cell: an elusive target for therapeutic intervention.
Brewer HB
J Clin Invest; 2000 Mar; 105(6):703-5. PubMed ID: 10727436
[No Abstract] [Full Text] [Related]
30. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
[TBL] [Abstract][Full Text] [Related]
31. The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine.
Burrier RE; Smith AA; McGregor DG; Hoos LM; Zilli DL; Davis HR
J Pharmacol Exp Ther; 1995 Jan; 272(1):156-63. PubMed ID: 7815329
[TBL] [Abstract][Full Text] [Related]
32. [Acyl-coenzyme A: cholesterol acyltransferase (ACAT)].
Miyazaki A; Watanabe T
Nihon Rinsho; 2004 Dec; 62 Suppl 12():89-91. PubMed ID: 15658270
[No Abstract] [Full Text] [Related]
33. Acyl-CoA : cholesterol acyltransferase inhibitors from Magnolia obovata.
Kwon BM; Kim MK; Lee SH; Kim JA; Lee IR; Kim YK; Bok SH
Planta Med; 1997 Dec; 63(6):550-1. PubMed ID: 9434609
[TBL] [Abstract][Full Text] [Related]
34. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis.
Watanabe T; Nishio K; Kanome T; Matsuyama TA; Koba S; Sakai T; Sato K; Hongo S; Nose K; Ota H; Kobayashi Y; Katagiri T; Shichiri M; Miyazaki A
Circulation; 2008 Feb; 117(5):638-48. PubMed ID: 18212280
[TBL] [Abstract][Full Text] [Related]
35. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
Tomoda H; Doi T
Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
[TBL] [Abstract][Full Text] [Related]
36. HDL does not promote cholesterol efflux from macrophages of hypercholesterolemic rabbit: efflux differences between species.
Hayashi T; Yoshimine N; Naito M; Funaki C; Yamada K; Asai K; Kuzuya F
Artery; 1992; 19(4):184-98. PubMed ID: 1520072
[TBL] [Abstract][Full Text] [Related]
37. Esculeogenin A, a new tomato sapogenol, ameliorates hyperlipidemia and atherosclerosis in ApoE-deficient mice by inhibiting ACAT.
Fujiwara Y; Kiyota N; Hori M; Matsushita S; Iijima Y; Aoki K; Shibata D; Takeya M; Ikeda T; Nohara T; Nagai R
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2400-6. PubMed ID: 17872457
[TBL] [Abstract][Full Text] [Related]
38. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.
Kusunoki J; Hansoty DK; Aragane K; Fallon JT; Badimon JJ; Fisher EA
Circulation; 2001 May; 103(21):2604-9. PubMed ID: 11382731
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?
Heinonen TM
Curr Atheroscler Rep; 2002 Jan; 4(1):65-70. PubMed ID: 11772425
[TBL] [Abstract][Full Text] [Related]
40. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
Rudel LL; Lee RG; Parini P
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1112-8. PubMed ID: 15831806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
